Current therapy for LambertEaton myasthenic syndrome: Development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1363-1375

  Quartel, A ^a   Turbeville, S ^a   Lounsbury, D ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

3,4 diaminopyridine; Drug compounding; Drug therapy; Eaton myasthenic syndrome; Lambert; Neuromuscular junction diseases; Orphan drug production

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CISPLATIN; ETOPOSIDE; FIRDAPSE; GUANIDINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NEOSTIGMINE; PHYSOSTIGMINE; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; THEOPHYLLINE; UNCLASSIFIED DRUG; 3,4-DIAMINOPYRIDINE; DRUG DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT;

ABDOMINAL PAIN; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EATON LAMBERT SYNDROME; ECG ABNORMALITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; LACRIMATION; LIMB PAIN; LOADING DRUG DOSE; LOW DRUG DOSE; MICTURITION DISORDER; NAUSEA AND VOMITING; ORAL PARESTHESIA; PARANEOPLASTIC SYNDROME; PARESTHESIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; QT PROLONGATION; RECOMMENDED DRUG DOSE; RHINORRHEA; RISK BENEFIT ANALYSIS; SEIZURE; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; TORSADE DES POINTES; TREATMENT INDICATION; TREATMENT RESPONSE; WEAKNESS; ADULT; AGED; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

4-AMINOPYRIDINE; ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; POTASSIUM CHANNEL BLOCKERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77952535964     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003745209     Document Type: Short Survey

References (58)

1. Orphanet: Lambert-Eaton myasthenic syndrome. Available at: http://www. orpha.net [Last accessed 22 January 2010]
2. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956;187:612-613
3. Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7:1323-1336
4. Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002;104:359-363
5. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596
6. Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117-118
7. Elias A. Pathobiology and staging of small cell carcinoma of the lung. UpToDate. Available at: http://www.uptodate.com/online/content/topic. do?topicKey-lung-ca/5407&selectedTitle-1%7E150&source-search- result [Last accessed 22 January 2010]
8. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006;13:682-690
9. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-699
10. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immu-noglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-683
11. Commission of the European Communities. Commission decision of 18/12/2002 relating to the designation of medicinal product '3,4-diaminopyridine phosphate' as an orphan medicinal product. Brussels: C(2002)5445, 2002
12. Committee for medicinal products for human use. Committee for medicinal products for human use summary of positive opinion for ZENAS, International Nonproprietary Name (INN): amifampridine. London: EMEA/CHMP/655953/2009, 2009
13. Seneviratne U, de Silva R. Lambert-Eaton myasthenic syndrome. Postgrad Med J 1999;75:516-520
14. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73:766-768
15. Gracey DR, Southorn PA. Respiratory failure in Lambert-Eaton myasthenic syndrome. Chest 1987;91:716-718
16. Orphanet: Myasthenia gravis. Available at: http://www.orpha.net [Last accessed 22 January 2010]
17. Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87
18. Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthe-nic syndrome. J Neurol Sci 1997;147:35-42
19. Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1998;65:213-217 (Pubitemid 28371933)
20. Titulaer MJ, Wirtz PW, Kuks JBM, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008;201-2:153-158
21. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthe-nic syndrome. J Neuroimmunol 2005;159:230-237
22. Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:4276-4281
23. Zivaljević M, Popović S, Vujkov T. [Lambert-Eaton myasthenic syndrome-a rare manifestation of paraneoplastic syndrome in ovarian cancer-case report]. Med Pregl 2005;58:495-497
24. Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672
25. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, et al. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev 2009;CD001990
26. Kelly K. First-line chemotherapy for small cell lung cancer. UpToDate. Available at: http://www.uptodate.com/online/content/topic.do?topicKey- lung-ca/6976&selectedTitle-2%7E150&source-search-result [Last accessed 22 January 2010]
27. 2\+ flux in a human small cell carcinoma line. Nature 1985; 317:737-739
28. Peterlin BL, Flood W, Kothari MJ. Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome. J Am Osteopath Assoc 2002; 102:682-684
29. Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009;40:305-308
30. Ueda T, Kanda F, Kobessho H, et al. 'Dropped head syndrome' caused by Lambert-Eaton myasthenic syndrome. Muscle Nerve 2009; 40:134-136
31. Kostera-Pruszczyk A, Ryniewicz B, Rowinska-Marcinska K, et al. Lambert-Eaton myasthenic syndrome in childhood. Eur J Paediatr Neurol 2009; 13:194-196
32. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44-48
33. Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 1983;227:260-265
34. Murray NMF, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-271
35. Lundh H, Nilsson O, Rosén I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-1330
36. Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980;61:25-34
37. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005;CD003279
38. Lemeignan M, Millart H, Lamiable D, et al. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 1984;304:166-169
39. Lundh H, Nilsson O, Rosén I. Novel drug of choice in Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1983;46:684-685
40. McEvoy KM, Windebank AJ, Daube JR, et al. 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321:1567-1571
41. Sanders DB, Massey JM, Sanders LL, et al. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-607
42. Sanders DB, Howard Jr JF, Massey JM. 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann N Y Acad Sci 1993;681:588-590
43. Oh SJ, Claussen GG, Hatanaka Y, et al. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009;40:795-800
44. Murray NMF, Newsom-Davis J, Karni Y, et al. Oral 3,4-diaminopyridine in the treatment of the Lambert-Eaton myasthenic syndrome (LEMS). Proceedings of the meeting of the Association of British Neurologists held jointly with the Polish Neurological Society in London, April 1984. J Neurol Neurosurg Psychiatry 1984;47:1052
45. Flet L, Polard E, Guillard O, et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010; doi:10.1007/s00415-009-5442-6
46. Spatt J, Chaix R, Mamoli B. Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol 2001;248:2-9
47. Boerma CE, Rommes JH, van Leeuwen RB, et al. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol 1995; 33:249-251
48. Lundh H, Nilsson O, Rosén I, et al. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 1993;88:136-140
49. Kanzato N, Motomura M, Suehara M, et al. Lambert-Eaton myasthenic syndrome with ophthalmoparesis and pseudoblepharospasm. Muscle Nerve 1999;22:1727-1730
50. Burton JM, Bell CM, Walker SE, et al. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71:1833-1834
51. Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2009: published online 12 May 2009, doi:10.1016/j.jemermed.2009.04.037
52. Limited FDA survey of compounded drug products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2003. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm [Last accessed 22 January 2010]
53. Raust JA, Goulay-Dufaÿ S, Le Hoang MD, et al. Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products. J Pharm Biomed Anal 2007; 43:83-88
54. Common technical document Zenas® 10 mg, scored tablets-3,4-DAP phosphate (INN: amifampridine). Module 2.4. Non-clinical overview
55. Common technical document Zenas® 10 mg, scored tablets-3,4-DAP phosphate (INN: amifampridine). Module 2.5. Clinical overview
56. Funck-Bretano C. Relative bioavailability study of 3,4-DAP administered as a salt or a base. DAPSEL study. Clinical study report. February 2006
57. Common technical document Zenas® 10 mg, scored tablets-3,4-DAP phosphate (INN: amifampridine). Module 5.3.5.4.3. Prospective collection of safety data from patients treated with 3,4-diaminopyridine under French ATU program
58. Warning letter sent by AFSSaPS to health professionals on December 11th 2006 Xyzal [package insert].